Work

Targeting GCN5-mediated ERK lactylation: A promising drug development frontier in cancer therapy

Year: 2026

Type: article

Abstract: • GCN5 mediates ERK K231 lactylation linking glycolysis to oncogenic MAPK signaling. • Targeting GCN5 lactylation offers a strategy to overcome resistance to MEK or ERK inhibitors. • Modulating lactylation reshapes the tumor immune microenvironment and enhances T cell function. • Inhibiting site-specific lactylation is a precise strategy for glycolytic RAS ERK driven cancers.

Source: Biomedicine & Pharmacotherapy

DOI: 10.1016/j.biopha.2026.119128

Authors: Yen-Dun Tony Tzeng, An-Jen Chiang, Chia-Jung Li

Institutions: Kaohsiung Veterans General Hospital, National Sun Yat-sen University, National Museum of Marine Biology and Aquarium, Cheng Shiu University

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,610